Rose Franco, MD
Pulmonary Disease · Milwaukee, WINPI 1821040494
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $857 of the $993 with a category attached, or 86.3%. It is spread thinly across 16 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $312, 3.2 times the $96 reported in 2019.
Across 45 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viatris Specialty LLC$120
- AbbVie$117
- Baxter Healthcare$116
- Vertex$114
- Advanced Respiratory, Inc$82
- Gilead$81
- plus $363 from 10 others
Across 1 payment — averaging $5000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Harmony Biosciences LLC$5K
What the payments were for
- Food & beverage$85786%
- Education$13614%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viatris Specialty LLC | 2 | $120 |
| AbbVie | 5 | $117 |
| Baxter Healthcare | 3 | $116 |
| Vertex | 6 | $114 |
| Advanced Respiratory, Inc | 4 | $82 |
| Gilead | 5 | $81 |
| Nestle Healthcare Nutrition Inc. | 2 | $56 |
| Mylan Specialty L.p. | 3 | $56 |
| Electromed, Inc. | 4 | $47 |
| Vivus LLC | 2 | $37 |
| Philips North America LLC | 2 | $36 |
| AstraZeneca | 2 | $35 |
| Amgen | 1 | $34 |
| Chiesi USA, Inc. | 2 | $31 |
| GSK | 1 | $19 |
| Novartis | 1 | $12 |
How this compares
$993 in reported general payments places this provider in the 55th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 44 | $1,172,257 |
| SymdekoTezacaftor/Ivacaftor | 12 | $265,462 |
| Fasenra PenBenralizumab | 37 | $212,688 |
| CreonLipase/Protease/Amylase | 43 | $194,543 |
| CaystonAztreonam Lysine | 17 | $194,456 |
| Dupixent PenDupilumab | 48 | $173,283 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 108 | $112,022 |
| NucalaMepolizumab | 21 | $96,826 |
| Spiriva HandihalerTiotropium Bromide | 40 | $46,380 |
| TezspireTezepelumab-Ekko | 11 | $45,979 |
| SymbicortBudesonide/Formoterol Fumarate | 85 | $35,835 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 33 | $34,578 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $33,537 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $26,901 |
| Spiriva RespimatTiotropium Bromide | 42 | $26,549 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta, Symdeko | $114 | $1,437,72056 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $19 | $298,109281 claims |
| AbbVieCreon | $117 | $194,54343 claims |
| GileadCayston | $81 | $194,45617 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere, Pulmicort Flexhaler | $35 | $106,793141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 247 pulmonary disease providers in Wisconsin.
Other pulmonary disease in Milwaukee
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
- Kurt HuMilwaukee$55K
- Julie BillerMilwaukee$52K
- Mark BarashMilwaukee$52K
- Rahul NanchalMilwaukee$42K
- Steven LehMilwaukee$40K
- Ali MusaniMilwaukee$38K
- Michael KatzoffMilwaukee$37K
- Uzair GhoriMilwaukee$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.